AGRX At FDA Altar Again, AZN Falls As MYSTIC Fails, VBIV Delivers A Good Shot

Today's Daily Dose brings you news about Agile's regulatory catalyst for this year; AstraZeneca's disappointing results from MYSTIC trial; Tetraphase's stock offering and VBI Vaccines' positive interim data from its preventative cytomegalovirus vaccine study.

from RTT - Biotech http://ift.tt/2u3KOoz
via IFTTT